Visgene has been advancing research and development to bring antibody technology for identifying all four dengue virus serotypes into practical medical use. We are pleased to announce that our product, “VisCheck™ Dengue NS1 Rapid Antigen Serotyping Test,” has now received in vitro diagnostic device registration from the Food and Drug Administration of the Kingdom of Thailand. Sales within Thailand will begin in January 2025.
Product information
- Year of launch：2025
- Unit of sale：1 box (25 test)
- Company name VisGene Ltd
- Model number VCDV066, VisCheck DVNS1 – 25 test/Box
Targeted health issues and product overview
This product is an NS1 serotype-specific diagnostic kit for the detection of dengue virus. Dengue fever is endemic in over 100 countries, particularly in Southeast Asia, Latin America, and Africa, with approximately 400 million infections annually.
This kit enables high-sensitivity detection of the NS1 antigen from serum and allows for rapid identification of the infecting dengue serotype (types 1–4).
Since secondary infection with a different serotype increases the risk of severe illness, serotype-specific diagnosis is of growing importance.
While the case fatality rate can reach 20–30% without appropriate treatment following severe symptoms, proper clinical management is expected to reduce the rate to below 0.5%.